Page 488 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

446 MEDICAMENTS INDUISANT OUSTABILISANTDES COUPURES DE L'ADN

Leurubicin, Drugs Future, 1993, 18, 116-120.
HERTZBERG R.P. et al., Antineoplastic Agents, Annu. Rep. in Mead. Chem., 1993, vol.
28, chap. 18, p. 167-176, Academic Press, London.
ARCAMONE F., Design and synthesis of anthracycline and distamycin derivatives as new
sequence-specific DNA-binding pharmacological agents, Gene, 1994, 149, 57-61.
LAU D. H. M. et al., Metabolic conversion of methoxymorpholinyl doxorubicin : from a
DNA strand breaker to a DNA cross-linker, Br. J. Cancer, 1994, 70, 79-84.
VASEY P. A. et al., Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-
methoxy-4-morpholinyl)doxorubicin (FCE 23762), CancerRes., 1995, 55, 2090-2096.
ANIMATl F. et al., New anthracycline disaccharides. Synthesis of L-daunosaminyl-a(1'4)-
2-deoxy-L-rhamnosyl and of L-daunosaminyl-a(1'-4)-2-deoxy-2-fucosyl daunorubi-
cin analogues, J. Chem. Soc., Perkin Trans./, 1996, 1327-1329.
PASQUI F et al., Synthesis of ring A fluorinated anthracyclines, Tetrahedron, 1996, 52,
185-192.
DA 125, Drugs Future, 1996, 21, 782-786; 1997, 22, 899.
ARCAMONE F., Doxorubicin disaccharide analogue: apoptosis-related improvment of
efficacy in vivo, J. Natl. Cancer Inst., 1997, 89, 1217-1223.
CHAIRES J. B. et al., Structure-based design of a new bisintercalating anthracycline anti-
biotic, J. Med. Chem., 1997, 40, 261-266.
GRAULA. etal., Annamycin LF, Drugs Future, 1997, 22, 948-955.
HU G.G. et al., Structure of a DNA-bisdaunomycine complex. Biochemistry, 1997, 36,
5940-5946.
SIM S. P. et al., Differential poisoning of topoisomerases by menogaril and nogalamycin dic-
tated by the minorgroove-binding nogalose-sugar, Biochemistry, 1997, 36, 13285-13291.
SWEATMAN T. W., ISRAEL M., Anthracyclines, chapter 5 in Cancer Therapeutics : Expe-
rimental and clinicat agents, Edit. TEICHER B. A. ; Publ. Humana Press, Totowa, NJ ;
1997, 113-136.
Nemorubicine, Drugs Future, 1997, 22, 1319-1324.
ARCAMONE F., From the pigments of the actinomycetes ta third generation antitumor
anthracyclines, Biochimie, 1998, 80, 201-206.
LENG F. et al., Ultratight DNA binding of a new bisintercalating anthracycline antibiotic.
Biochemistry, 1998, 37, 1743-1753.
SU J., WULFF W. D., Synthesis of the tetracyclic carbon core of Menogaril utilizing the
benzannulation reaction or a Fischer carbene complex and an alkyne, J. Org. Chem.,
1998, 63, 8440-8447.
PRATESI G. et al., lmproved efficacy and enlarged spectrum of activity of a novel anthra-
cycline disaccharide analogue of doxorubicine against human tumor xenografts, Clin.
CancerRes., 1998, 4, 2833-2839.
KANG Y.K. et al., A phase Il trial of DA-125, a navel anthracycline in advanced non small-
cell lung cancer, Cancer Chemother. Pharmacol., 1999, 44, 518-521.
KATSUMATA N. et al., Phase 11 study of KRN8602, 3'-deamino-3'-morpholino-13-
deoxo-10-hydroxycarminomycin hydrochloride, MX2 • HCI in patients with metastatic
breast cancer, Cancer Chemother. Pharmacol., 1999, 43, 441-444.
MARTIN B. et a/., Bisanthracycline WP631 inhibits basal and Sp1-activated transcription
initiation in vitro, Nuclelc Aclds Res., 1999, 27, 3402-3409.